1. Fig. 3. Fc fusion GDF15 molecules improve metabolic parameters in obese mice and obese cynomolgus monkeys.
Fc fusion GDF15 molecules improve metabolic parameters in obese mice and obese cynomolgus monkeys. (A) Body weight, OGTT glucose AUC, insulin, triglyceride, cholesterol concentrations, and food intake of male C57BL/6 DIO mice treated weekly with vehicle, rosiglitazone, or Fc fusion GDF15 proteins (0.1, 1, or 10 nmol/kg) for 5 weeks (n = 12). *P < 0.05, **P < 0.01, and ***P < versus vehicle by ANOVA. (B and C) Cynomolgus monkeys received weekly subcutaneous doses (days 0, 7, 14, 21, 28, and 35) of vehicle (closed square; n = 10), ScFc (open triangle; n = 5), or DhCpmFc (open circle; n = 8) for 6 weeks. (B) Plasma chemistries and body weights were measured 6 days after each weekly injection before the morning meal (days 6, 13, 20, 27, 34, and 41); food intake measurements occurred daily. Data are expressed as group means ± SEM. (C) OGTT data are represented as AUC (glucose AUC, mg/dl per hour; insulin AUC, ng/ml per hour; 0 to 180 min). Cynomolgus monkeys suspected to be positive for anti-GDF15 antibodies were excluded from data analysis (five monkeys for ScFc and two for DhCpmFc). Statistical analysis was performed by analysis of covariance (ANCOVA), and statistical significance is denoted as #P < 0.05, ##P < 0.01, and ###P < 0.01 versus vehicle for ScFc; *P < 0.05, **P < 0.01, and ***P < 0.01 versus vehicle for DhCpmFc.
Yumei Xiong et al., Sci Transl Med 2017;9:eaan8732
Published by AAAS